top of page

North America Tissue Technical Advisory Group


The North America Tissue Technical Advisory Group (NATTAG) was formed in 2006. Its members are from the US and Canada. This regional TAG operates under the direction and guidance of the International Tissue Technical Advisory Group (ITTAG).

The purpose of NATTAG is to:

  • Develop a consensus on the detailed implementation of ISBT 128 in North America and maintain a North America consensus document for the use of ISBT 128 on tissues;

  • Contribute towards the international standardization of tissue terminology and product naming;

  • Provide advice and support to facilities introducing the ISBT 128 Standard in North America;

  • Advise on the on-going development of the ISBT 128 standard to support new developments in tissue banking in North America;

  • Prepare educational material and tools to support the implementation of ISBT 128 in North America; and

  • Promote the adoption of the ISBT 128 Standard in tissue banking in North America.


NATTAG is assessing the need for a unique identifier to link the different donation identifiers used by diverse organizations involved in the procurement of tissues and organs from a single donor. This topic has been brought up for discussion because the current practice directly impacts the ability to identify rapidly, quarantine, and recall tissues and organs involved in a potential recall for a process deviation, late notification, or adverse event, which could result in potential or suspected donor-derived disease transmission.


During the COVID-19 pandemic, some ocular facilities reported an approximately 20% decrease in the number of transplants and patient recovery. In addition, some hospitals reported to have canceled elected surgeries; thus, the need for tissues decreased. NATTAG is looking into the possibility of publishing an article that captures the global implications of COVID-19 for the industry.


The committee members reviewed the NATTAG Terms of Reference. ICCBBA reported the committee’s recommendations to the Standards Committee at the meeting on November 18, 2021.



  • Jelena Holovati


  • Albert Anouna – BioGenetics Corp.

  • Rhubella Arata – One Legacy

  • Esther Carbon – RTI Bilogics

  • Jennifer DeMatteo – Eye Bank Association of America

  • Robin Fowler – LifeLink Foundation, Inc.

  • Mark Friedman – AxoGen, Inc.

  • Kip Hanks – American Association of Tissue Banks

  • Mohamed Harunani – American Dental Association

  • Becky Holman – DCI Donor Services Tissue Bank
    Manager RA & QC

  • Ken Lotherington – Canadian Blood Services

  • Eric Nagel – Community Blood and Tissue Services

  • Mike Poole – LifeNet Health

  • Donna Ridder – Cryobiology, Inc.

  • David Tinker –  MTF Biologics

  • Elkin Vasquez – Vivex biologics


  • Geoff Browne

  • Jeff Dragoo

  • Sharon Joyner

  • Andrew Keelor

  • Brian Kirkpatrick

  • John Kling

  • Paul Lehner

  • Susan Tibedo

Technical Experts

  • Diane Wilson

ICCBBA Staff Liaison

  • Mónica Freire


  • Scott Brubaker – U.S. Food and Drug Administration / Center for Biologics Evaluation and Research

  • Barry Daniels – Global Medical Device Nomenclature

  • Mark Wasmuth – Global Medical Device Nomenclature

  • Izabela Uhrynowska-Tyszkiewicz – ITTAG

bottom of page